115 related articles for article (PubMed ID: 6519580)
1. [Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis].
Koshiyama Y; Ozeki M; Motoyoshi A; Fujita M; Iwaki M; Aoyama T
Nihon Yakurigaku Zasshi; 1984 Nov; 84(5):417-28. PubMed ID: 6519580
[TBL] [Abstract][Full Text] [Related]
2. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Akizawa T
Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
[TBL] [Abstract][Full Text] [Related]
3. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
[TBL] [Abstract][Full Text] [Related]
4. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
[TBL] [Abstract][Full Text] [Related]
5. [The inhibitory effect of nafamostat mesilate (FUT-175) on liver metastasis].
Kimura T; Fuchimoto S; Iwagaki H; Orita K
Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):66-70. PubMed ID: 8437554
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L
J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301
[TBL] [Abstract][Full Text] [Related]
7. Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis.
Gabryelewicz A; Prokopowicz J; Bodzenta A; Bielecki W; Rydzewska G
Digestion; 1988; 40(1):19-24. PubMed ID: 3234615
[TBL] [Abstract][Full Text] [Related]
8. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
Cook NS; Bruttger O; Pally C; Hagenbach A
Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
[TBL] [Abstract][Full Text] [Related]
9. Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid.
Panes O; Padilla O; Matus V; Sáez CG; Berkovits A; Pereira J; Mezzano D
Platelets; 2012; 23(1):36-44. PubMed ID: 21787173
[TBL] [Abstract][Full Text] [Related]
10. The anticoagulant effects of the hookworm, ancylostoma ceylanicum: observations on human and dog blood in vitro and infected dogs in vivo.
Carroll SM; Howse DJ; Grove DI
Thromb Haemost; 1984 Apr; 51(2):222-7. PubMed ID: 6740554
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis].
Iwaki M; Ozeki M; Sato T; Suzuki K; Motoyoshi A; Suzuki S; Fujita M; Aoyama T
Nihon Yakurigaku Zasshi; 1984 Oct; 84(4):363-72. PubMed ID: 6210233
[TBL] [Abstract][Full Text] [Related]
12. Effects of alpha-tocopherol on platelets and the coagulation system.
Bakaltcheva I; Gyimah D; Reid T
Platelets; 2001 Nov; 12(7):389-94. PubMed ID: 11674855
[TBL] [Abstract][Full Text] [Related]
13. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity.
Berry CN; Lassalle G; Lunven C; Altenburger JM; Guilbert F; Lalé A; Hérault JP; Lecoffre C; Pfersdorff C; Herbert JM; O'Connor SE
J Pharmacol Exp Ther; 2002 Dec; 303(3):1189-98. PubMed ID: 12438543
[TBL] [Abstract][Full Text] [Related]
14. In vitro effects of bencyclan on coagulation, fibrinolysis and platelet function.
Ponari O; Civardi E; Dettori G; Magha A; Potì R; Bulletti G
Arzneimittelforschung; 1976; 26(8):1532-8. PubMed ID: 12770
[TBL] [Abstract][Full Text] [Related]
15. A critical role for thrombin in platelet aggregation under high shear stress.
Sakurai Y; Shima M; Giddings J; Takeyama M; Kasuda S; Nogami K; Nishiya K; Yoshioka A
Thromb Res; 2004; 113(5):311-8. PubMed ID: 15183043
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological studies of FUT-175, nafamstat mesilate. III. Anti-inflammatory activities of FUT-175].
Iwaki M; Oda M; Ozeki M; Ino Y; Suzuki K; Koshiyama Y; Motoyoshi A; Ogihara M; Suzuki S; Fujita M
Nihon Yakurigaku Zasshi; 1984 Oct; 84(4):373-84. PubMed ID: 6239813
[TBL] [Abstract][Full Text] [Related]
17. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
[TBL] [Abstract][Full Text] [Related]
18. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
19. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
20. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients.
Miyata M; Shirakawa T; Acharya B; Terao S; Gotoh A
ASAIO J; 2006; 52(3):272-5. PubMed ID: 16760715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
